首页> 外文OA文献 >MP361EFFICACY AND SAFETY OF A NOVEL INTRAVENOUS CALCIMIMETIC, ONO-5163 (ETELCALCETIDE) IN JAPANESE HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM : RESULTS OF A PLACEBO CONTROLLED PHASE III STUDY

【2h】

MP361EFFICACY AND SAFETY OF A NOVEL INTRAVENOUS CALCIMIMETIC, ONO-5163 (ETELCALCETIDE) IN JAPANESE HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM : RESULTS OF A PLACEBO CONTROLLED PHASE III STUDY

机译：新型静脉注射钙质，ONO-5163（Etelcalcetide）在日本血液透析患者中的新型静脉注射患者的MP36减少和安全性：安慰剂控制第三阶段研究的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Masafumi Fukagawa; Keitaro Yokoyama; Takashi Shigematsu; Takashi Akiba; Akifumi Fujii; Takuto Kuramoto; Motoi Odani; Tadao Akizawa;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A 12-week dose-escalating study of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients [J] . Yokoyama Keitaro, Fukagawa Masafumi, Shigematsu Takashi, Clinical nephrology . 2017,第2期

机译：一种12周的剂量升级的精体升级（ONO-5163 / AMG 416），一种新的静脉内钙化，用于日本血液透析患者的继发性甲状旁腺功能亢进症
2. FAIRY: a randomized controlled patient-blind phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose (Ferinject?) to placebo in patients with acute isovolemic anemia after gastrectomy - study protocol for a randomized controlled trial [J] . Daniel Reim, Young-Woo Kim, Byung H Nam, Trials . 2014,第1期

机译：公平：一项随机对照的患者盲III期研究，比较了胃切除术后急性等容性贫血患者中静脉注射羧甲基麦芽糖铁（Ferinject？）与安慰剂的疗效和安全性-一项随机对照试验的研究方案
3. Golimumab, a new human anti–tumor necrosis factor antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study † [J] . Joel Kremer, Christopher Ritchlin, Alan Mendelsohn, Arthritis & Rheumatism . 2010,第4期

机译：Golimumab，一种新型的人类抗肿瘤坏死因子抗体，在活动性类风湿关节炎患者中静脉给药：III期随机，双盲，安慰剂对照研究的48周疗效和安全性结果†
4. Phase I Double Blind, Placebo Controlled, Ascending Single Intravenous Dose Study with a Synthetic Direct Thrombin Inhibitor, TGN255 [C] . S. Combe, G. Allen, T. Kennedy International Congress on Thrombosis . 2004

机译：I阶段双盲，安慰剂控制，用合成直接凝血酶抑制剂升序单静脉注射剂量研究，TGN255
5. Impact of Long-Term Intravenous Vitamin D on Parathyroid Hormone, Calcium, and Phosphorus in Hemodialysis Patients with Secondary Hyperparathyroidism. [D] . Sarkissian Pekacheki, Ivet. 2012

机译：长期静脉给予维生素D对继发性甲状旁腺功能亢进的血液透析患者甲状旁腺激素，钙和磷的影响。
6. A phase 3 multicentre randomized double-blind placebo-controlled parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416) a novel intravenous calcimimetic for secondary hyperparathyroidism in Japanese haemodialysis patients [O] . Masafumi Fukagawa, Keitaro Yokoyama, Takashi Shigematsu, -1

机译：一项三期多中心随机双盲安慰剂对照平行组研究用于评估新型静脉拟钙剂ecalccalcetide（ONO-5163 / AMG 416）对日本血液透析患者继发性甲状旁腺功能亢进的疗效和安全性
7. Faculty Opinions recommendation of Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study. [O] . Mariano Rodriguez, María E Rodríguez 2020

机译：教师意见建议Evocalcet（KHK7580），一种新型钙质，在日本患者中进行血液透析的患者：随机，双盲，安慰剂，剂量寻找研究。

MP361EFFICACY AND SAFETY OF A NOVEL INTRAVENOUS CALCIMIMETIC, ONO-5163 (ETELCALCETIDE) IN JAPANESE HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM : RESULTS OF A PLACEBO CONTROLLED PHASE III STUDY

著录项

相似文献

相关主题

期刊订阅